Pathstone Holdings
EDIT icon

Pathstone Holdings’s Editas Medicine EDIT Stock Holding History

Pathstone Holdings’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,530
Closed -$12.2K – 2225
2025
Q1 		$12.2K Sell
10,530
-275
-3% -$405 ﹤0.01% 2215
2024
Q4 		$13.7K Sell
10,805
-4,932
-31% -$12.6K ﹤0.01% 2293
2024
Q3 		$53.7K Buy
+15,737
New +$68.5K ﹤0.01% 2280

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Pathstone Holdings's EDIT Position: Q2 2025 in Review

Pathstone Holdings sold out of Editas Medicine (EDIT) in Q2 2025, closing a stake of 10,530 shares — an estimated $12.2K sold.

Pathstone Holdings first reported a position in EDIT in Q3 2024 and held it in 3 quarters. The position peaked at $53.7K in Q3 2024. 194 funds tracked by Wall St. Rank hold EDIT as of Q2 2025.

  • Pathstone Holdings reported no remaining Editas Medicine position as of Q2 2025 after selling out during the quarter.
  • Pathstone Holdings sold 10,530 Editas Medicine shares in Q2 2025, an estimated $12.2K.
  • Pathstone Holdings first reported a position in Editas Medicine in Q3 2024 and held it in 3 quarters.
  • Pathstone Holdings's Editas Medicine position peaked at $53.7K in Q3 2024.
  • 194 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2025.

Based on Pathstone Holdings's 13F filing for Q2 2025, filed 12 Aug 2025.